Riliprubart

瑞扑拜单抗

Report date: 2026/03/28 20:00:32

Base Information

Drug NameRiliprubart
Drug Alias NameBIVV-020SAR-445088TNT-020
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C1s inhibitors
TargetsComplement C1s
Therapy Area/IndicationsGraft RejectionPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTrue North Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBioverativ, A Sanofi CompanySanofiSanofi-Aventis Recherche & Developpement +[4] 
Inactive CompaniesN/A
Active IndicationsGraft RejectionPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingPolyradiculoneuropathy +[4] 
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune

Other Information

ATC CodeN/A
Related LinksN/A